Stayble Therapeutics
0.398
SEK
+3.11 %
STABL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+3.11%
-33.67%
-39.24%
+46.32%
+31.35%
+26.35%
-93.73%
-
-94.68%
Stayble Therapeutics operates in the pharmaceutical industry. The company specializes in research and development of injection treatments for pain caused by herniated discs. The drug candidates are developed and based on a proprietary technological platform. Most operations are found in the Nordic market and the company has its headquarters in Gothenburg.
Read moreMarket cap
17.4M SEK
Turnover
54.36K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
25/2
2025
Annual report '24
ShowingAll content types
Stayble Therapeutics: Staybles VD, Andreas Gerward, presenterade vid Financial Stockholm den 11 december 2024
Stayble Therapeutics reports additional data strengthening the STA363 treatment for pain caused by disc herniation
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools